Link to this page
Physician Data Query
| Preferred Name | pegfilgrastim | |
| Synonyms |
PEG-rhG-CSF SD-01 Fulphila HSP-130 filgrastim-SD/01 Jinyouli pegfilgrastim biosimilar pegcyte Neulasta Filgrastim SD-01 Neulastim GCSF-SD01 SD-01 sustained duration G-CSF |
|
| Definitions |
A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1854" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1854" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000037807 |
|
| altLabel |
PEG-rhG-CSF SD-01 Fulphila HSP-130 filgrastim-SD/01 Jinyouli pegfilgrastim biosimilar pegcyte Neulasta Filgrastim SD-01 Neulastim GCSF-SD01 SD-01 sustained duration G-CSF
|
|
| CAS Registry |
208265-92-3
|
|
| Component of |
http://purl.bioontology.org/ontology/PDQ/CDR0000405881 http://purl.bioontology.org/ontology/PDQ/CDR0000335444 http://purl.bioontology.org/ontology/PDQ/CDR0000361785 http://purl.bioontology.org/ontology/PDQ/CDR0000357560 http://purl.bioontology.org/ontology/PDQ/CDR0000335445 http://purl.bioontology.org/ontology/PDQ/CDR0000361549 |
|
| cui |
C4087036 C1171279 C4727809 C4732932 C3852764 C4703819 C4287820 C1136535
|
|
| Date last modified |
2018-08-27
|
|
| definition |
A long-acting pegylated form of a recombinant therapeutic agent which is chemically identical to or similar to an endogenous human granulocyte colony-stimulating factor (G-CSF). Produced endogenously by monocytes, fibroblasts, and endothelial cells, G-CSF binds to and activates specific cell surface receptors, stimulating neutrophil progenitor proliferation and differentiation and selected neutrophil functions. Conjugation of the cytokine with a branched polyethylene glycol molecule (pegylation) significantly increases its therapeutic half-life. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C1854" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C1854" NCI Thesaurus)
|
|
| Legacy PDQ ID |
10165
|
|
| LT |
TRD
|
|
| NCI ID |
C1854
|
|
| notation |
CDR0000037807
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
pegfilgrastim
|
|
| tui |
T109 T116 T129 T123 T121
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |